ArticleIntestinal research2016
Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries.
Article in Intestinal research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04129723 (Stopping Biological Therapy in Perianal Crohn's Disease Patients With Radiologically Healed Fistulas), which is not on this map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Stopping Biological Therapy in Perianal Crohn's Disease Patients With Radiologically Healed Fistulas: a Prospective Cohort Study
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2025Pooled it
- Disease experiences and perspectives of adolescent patients with inflammatory bowel disease: a meta-synthesis of qualitative research.Frontiers in public health · 2025Pooled it
- Review
- Health-related quality of life in IBD patients with long COVID under China's normalized COVID-19 management.BMC infectious diseases · 2026Article
- Crohn's Disease in Malaysia: Could Application of the Precautionary Principle Reduce Future Incidence?Microorganisms · 2026Review
- Global Variability in the Management of Inflammatory Bowel Disease: Towards Context-Specific Strategies.Cureus · 2025Review
- Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition.Intestinal research · 2025Review
- Reflections from Chinese and Japanese Physicians on Medical Disputes.Asian bioethics review · 2024Article
- Study of Inflammatory Bowel Disease in Patients Undergoing Colonoscopy at a Tertiary Center of Nepal.Cureus · 2024Article
- IBD barriers across the continents - East Asia.Therapeutic advances in gastroenterology · 2023Review
- Identification of the informational and supportive needs of patients diagnosed with inflammatory bowel disease: a scoping review.Frontiers in psychology · 2023Article
- Landscape of inflammatory bowel disease in Singapore.Intestinal research · 2022Review
- Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis-Patients' and Physicians' View.Inflammatory bowel diseases · 2021Article
- Inflammatory bowel disease in India: challenges and opportunities.Frontline gastroenterology · 2021Article
- Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.Digestive diseases and sciences · 2020Article
- Incidence and Outcomes of Perianal Disease in an Asian Population with Crohn's Disease: A Nationwide Population-Based Study.Digestive diseases and sciences · 2020Article
- Review of the epidemiology and burden of ulcerative colitis in Latin America.Therapeutic advances in gastroenterology · 2020Review
- Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.Intestinal research · 2019Review
- Initial medical and surgical management of inflammatory bowel disease in the biologic era: A comparison between the United States and China.JGH open : an open access journal of gastroenterology and hepatology · 2019Article
- Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study.Intestinal research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsThe cost of caring for patients with inflammatory bowel disease (IBD) is high. Without government support, the cost burden will unavoidably rest on the patients and their family. However, the government providing full support will place a large financial burden on the health-care systems of a country. The aim of this study is to understand the current status of public medical insurance systems in caring for IBD patients among Asian countries.
methodsQuestionnaires inquiring about the availability of public health systems; medical, diagnostic, and endoscopy costs; and coverage rate of biologics use were designed and sent to IBD experts in each of the Asian countries studied. The results were summarized according to the feedback from the responders.
resultsThe public health insurance coverage rate is high in Taiwan, Japan, South Korea, China, Hong Kong, and Singapore; but low in Malaysia and India. This probably affected the use of expensive medications mostly, such as biologics, as we found that the percentage of Crohn's disease (CD) treated with biologics were as high as 30%-40% in Japan, where the government covers all expenses for IBD patients. In India, the percentage maybe as low as 1% for CD patients, most of whom need to pay for the biologics themselves.
conclusionsThere were differences in the public health insurance systems among the Asian countries studied. This reportprovidesthe background information to understand the differences in the treatment of IBD patients among Asian countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.